Yeahka Valuation
Is 9923 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9923 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9923 (HK$9.87) is trading below our estimate of fair value (HK$12.46)
Significantly Below Fair Value: 9923 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9923?
Key metric: As 9923 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 9923's PS Ratio? | |
|---|---|
| PS Ratio | 1.1x |
| Sales | CN¥3.47b |
| Market Cap | CN¥3.93b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | -89.5x |
| PEG Ratio | 10.2x |
Price to Sales Ratio vs Peers
How does 9923's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.3x | ||
2598 Lianlian DigiTech | 7.7x | 18.9% | HK$10.0b |
8279 AGTech Holdings | 3.9x | n/a | HK$2.4b |
818 Hi Sun Technology (China) | 0.4x | n/a | HK$1.1b |
1039 Changyou Alliance Group | 0.9x | n/a | HK$177.5m |
9923 Yeahka | 1.1x | 11.1% | HK$4.2b |
Price-To-Sales vs Peers: 9923 is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (3.3x).
Price to Sales Ratio vs Industry
How does 9923's PS Ratio compare vs other companies in the HK Diversified Financial Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
1152 Momentum Financial Holdings | 0.1x | n/a | US$9.46m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 9923 is good value based on its Price-To-Sales Ratio (1.1x) compared to the Hong Kong Diversified Financial industry average (1.9x).
Price to Sales Ratio vs Fair Ratio
What is 9923's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.1x |
| Fair PS Ratio | 1.2x |
Price-To-Sales vs Fair Ratio: 9923 is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$9.87 | HK$14.04 +42.3% | 10.7% | HK$16.70 | HK$12.30 | n/a | 8 |
| Nov ’25 | HK$10.96 | HK$14.04 +28.1% | 10.7% | HK$16.70 | HK$12.30 | n/a | 8 |
| Oct ’25 | HK$13.80 | HK$14.04 +1.7% | 10.7% | HK$16.70 | HK$12.30 | n/a | 8 |
| Sep ’25 | HK$10.70 | HK$13.99 +30.7% | 11.3% | HK$16.97 | HK$12.21 | n/a | 8 |
| Aug ’25 | HK$11.16 | HK$15.72 +40.8% | 11.7% | HK$19.66 | HK$13.50 | n/a | 7 |
| Jul ’25 | HK$10.00 | HK$15.68 +56.8% | 11.9% | HK$19.64 | HK$13.37 | n/a | 7 |
| Jun ’25 | HK$10.20 | HK$15.79 +54.9% | 11.1% | HK$19.76 | HK$13.46 | n/a | 8 |
| May ’25 | HK$10.30 | HK$15.79 +53.3% | 11.1% | HK$19.76 | HK$13.46 | n/a | 8 |
| Apr ’25 | HK$12.18 | HK$17.63 +44.7% | 30.6% | HK$32.14 | HK$13.47 | n/a | 9 |
| Mar ’25 | HK$12.66 | HK$21.07 +66.4% | 21.5% | HK$32.28 | HK$14.50 | n/a | 10 |
| Feb ’25 | HK$12.26 | HK$23.23 +89.5% | 16.6% | HK$32.37 | HK$19.79 | n/a | 9 |
| Jan ’25 | HK$14.72 | HK$23.87 +62.2% | 16.7% | HK$32.67 | HK$19.97 | n/a | 8 |
| Dec ’24 | HK$14.08 | HK$23.71 +68.4% | 16.4% | HK$32.36 | HK$20.23 | n/a | 8 |
| Nov ’24 | HK$14.56 | HK$23.30 +60.0% | 16.3% | HK$31.76 | HK$19.85 | HK$10.96 | 8 |
| Oct ’24 | HK$14.80 | HK$24.69 +66.8% | 15.7% | HK$31.98 | HK$19.99 | HK$13.80 | 11 |
| Sep ’24 | HK$15.60 | HK$24.69 +58.3% | 15.7% | HK$31.98 | HK$19.99 | HK$10.70 | 11 |
| Aug ’24 | HK$18.50 | HK$31.24 +68.8% | 11.6% | HK$38.75 | HK$26.77 | HK$11.16 | 11 |
| Jul ’24 | HK$17.50 | HK$31.36 +79.2% | 11.0% | HK$39.17 | HK$27.06 | HK$10.00 | 11 |
| Jun ’24 | HK$20.45 | HK$31.71 +55.0% | 11.1% | HK$39.89 | HK$27.56 | HK$10.20 | 11 |
| May ’24 | HK$21.45 | HK$32.12 +49.7% | 10.7% | HK$39.89 | HK$27.99 | HK$10.30 | 11 |
| Apr ’24 | HK$23.35 | HK$32.60 +39.6% | 10.3% | HK$40.00 | HK$28.68 | HK$12.18 | 10 |
| Mar ’24 | HK$27.55 | HK$29.85 +8.3% | 20.0% | HK$37.07 | HK$18.83 | HK$12.66 | 9 |
| Feb ’24 | HK$26.90 | HK$25.54 -5.1% | 23.2% | HK$38.01 | HK$19.31 | HK$12.26 | 7 |
| Jan ’24 | HK$20.95 | HK$24.37 +16.3% | 19.2% | HK$33.24 | HK$18.82 | HK$14.72 | 7 |
| Dec ’23 | HK$20.10 | HK$22.93 +14.1% | 18.9% | HK$31.85 | HK$18.04 | HK$14.08 | 8 |
| Nov ’23 | HK$18.96 | HK$21.75 +14.7% | 12.8% | HK$27.92 | HK$18.32 | HK$14.56 | 9 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Genertec Universal Medical Group
HK$8.8b
Offers financing and advisory services in the People’s Republic of China.
2666
HK$4.66
7D
-3.9%
1Y
11.2%
Noah Holdings
US$765.1m
Operates as a wealth and asset management service provider with the focus on investment and asset allocation services for high net worth individuals and enterprises in Mainland of China, Hong Kong, and internationally.
6686
US$20.85
7D
20.5%
1Y
4.5%
CSC Financial
HK$199.6b
Provides investment banking services in Mainland China and internationally.
6066
HK$9.88
7D
-5.4%
1Y
32.6%